Travere Therapeutics Revenue vs. Number Of Shares Shorted

TVTX Stock  USD 19.37  0.01  0.05%   
Based on Travere Therapeutics' profitability indicators, Travere Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Travere Therapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2013-12-31
Previous Quarter
54.1 M
Current Value
62.9 M
Quarterly Volatility
16.2 M
 
Yuan Drop
 
Covid
At this time, Travere Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. Days Sales Outstanding is likely to rise to 84.59 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 1.09 in 2024. At this time, Travere Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 234.2 K in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (1.4 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.070.9212
Fairly Up
Very volatile
For Travere Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Travere Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Travere Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Travere Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Travere Therapeutics over time as well as its relative position and ranking within its peers.
  

Travere Therapeutics' Revenue Breakdown by Earning Segment

Check out World Market Map.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.52)
Revenue Per Share
2.634
Quarterly Revenue Growth
0.696
Return On Assets
(0.26)
Return On Equity
(2.80)
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Travere Therapeutics Number Of Shares Shorted vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Travere Therapeutics's current stock value. Our valuation model uses many indicators to compare Travere Therapeutics value to that of its competitors to determine the firm's financial worth.
Travere Therapeutics is rated third in revenue category among its peers. It is rated below average in number of shares shorted category among its peers making about  0.05  of Number Of Shares Shorted per Revenue. The ratio of Revenue to Number Of Shares Shorted for Travere Therapeutics is roughly  20.83 . At this time, Travere Therapeutics' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Travere Therapeutics' earnings, one of the primary drivers of an investment's value.

Travere Revenue vs. Competition

Travere Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 980.29 Million. Travere Therapeutics retains roughly 145.24 Million in revenue claiming about 15% of equities under Health Care industry.

Travere Number Of Shares Shorted vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Travere Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
145.24 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Travere Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
6.97 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Travere Number Of Shares Shorted Comparison

Travere Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Travere Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Travere Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Travere Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Travere Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Travere Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-1.5 M-1.4 M
Operating Income-376.7 M-357.9 M
Income Before Tax-376.1 M-357.3 M
Total Other Income Expense Net634 K665.7 K
Net Loss-376.3 M-357.5 M
Income Tax Expense223 K234.2 K
Net Interest Income10.4 M11 M
Net Loss-376.3 M-357.5 M
Net Loss-250.6 M-238.1 M
Interest Income21.8 M22.9 M
Non Operating Income Net Other-295.2 K-280.4 K
Change To Netincome37.4 M43.7 M
Net Loss(1.50)(1.57)
Income Quality 0.74  0.78 
Net Income Per E B T 0.30  0.28 

Travere Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Travere Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Travere Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Travere Therapeutics' important profitability drivers and their relationship over time.

Use Travere Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Travere Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Travere Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Travere Therapeutics Pair Trading

Travere Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Travere Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Travere Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Travere Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Travere Therapeutics to buy it.
The correlation of Travere Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Travere Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Travere Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Travere Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Travere Therapeutics position

In addition to having Travere Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Air Thematic Idea Now

Air
Air Theme
Companies specializing in air services and air delivery. The Air theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Air Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.